ClinicalTrials.gg
RecruitingNCT06963359CHRONOSSARCREUpdated Feb 13, 2026

High-definition Surface Electromyography Markers for the Diagnosis and Monitoring of Sarcopenia

An interventional study of HD-sEMG and Quadriceps muscle ultrasound in Sarcopenia, sponsored by Assistance Publique - Hôpitaux de Paris. Recruiting at 11 sites in France. Open to participants aged 75 Years and older. Per ClinicalTrials.gov, last updated 2026-02-13.

Sponsored by Assistance Publique - Hôpitaux de Paris · Not applicable, Interventional, and Diagnostic

How we know

From the registry’s dates

  • Started Jul 2025; still recruiting 1 year 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
846
Allocation
Not applicable
Ages
75 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 78 studies in Sarcopenia with a site in France — 23 open to participants now, 24 under way, none of them phase 3. Sarcopenia · France.

Planned enrollment
2nd of 53
846 · median 98
Started
2025
with 8 others
No phase
49 of 78
18 open now
Primary completion
2027-03
later than 8 of 23 live
Registered
61st of 78
by date
Lead sponsor
4 of 78
Assistance Publique - Hôpitaux de Paris

Among the 78 studies in Sarcopenia with a site in France, this one is the 2nd largest by planned enrollment of the 53 interventional ones that give a count, is one of 9 that started in 2025, is one of 49 with no phase, reaches primary completion later than 8 of the 23 other live ones, and was the 61st registered.

Sarcopenia

1,334 studies on the registry are indexed under Sarcopenia; 418 are open to participants now.

Browse Sarcopenia studies →

Open to participants now

23 of the 78 studies in Sarcopenia with a site in France are open now. Recruiting first, the newest first:

17 more — sign in →

All 23 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 246 Sarcopenia studies recruiting now, 155 (63%) set no upper age limit and 32 (13%) stop at 75 or younger; 9 take children under 18; 62 take healthy volunteers.

This study: 75 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 78 studies in Sarcopenia with a site in France, or all of them as a file.
02

Study summary

Sarcopenia is a progressive and generalised skeletal muscle disorder involving the accelerated loss of muscle mass and function that is associated with increased adverse outcomes including falls, functional decline, frailty, and mortality. In this project, the high-definition surface electromyography technology (HD-sEMG) signals will be analysed to extract features/ markers for the diagnosis of sarcopenia. This is a multicentric, descriptive, cross-sectional, parallel group study to develop a new diagnostic method.

It is planned to include 846 people aged 75 years and over hospitalized in the acute geriatric or rehabilitation wards and suspected of sarcopenia (Score ≥4 on the SARC-F screening questionnaire). The inclusion duration will be 18 months and adding a 3-month patient follow-up. The total study duration will be 21 months. Patients will have their body composition using bioimpedancemetry and if possible by dual X-ray absorptiometry (DEXA). Muscular strength will be assessed by handgrip strength. Physical performance will be assessed. Additional data will be collected from their medical records.

Read the detailed description

The aging of the population is a major public health problem with its multifactorial impact on quality of life and maintenance of autonomy. Unfortunately, one consequence of aging is sarcopenia, which affects the intrinsic and functional properties of muscle. It is a risk factor for loss of autonomy, falls, frailty and is associated with increased mortality. Sarcopenia is defined as a progressive loss of muscle mass, strength and physical performance. Classically, sarcopenia is assessed by imaging techniques (MRI, DEXA) or bioelectrical impedancemetry for aspects related to the assessment of muscle mass loss. MRI or DEXA are not widely available and/or access is limited. For functional aspects, grip strength measurements are often used. Currently sarcopenia cannot be diagnosed and evaluated by a single examination, including both the morphological (muscle mass) and functional aspects. Furthermore, several biological markers are associated with muscle mass, strength, and function, but these biomarkers are not specific to skeletal muscle and are weakly associated with clinical goals. Finally, despite the important interest in assessing the qualitative/functional and quantitative aspect of skeletal muscle in neuromuscular impairment, there is currently no tool that routinely assesses these aspects. In this context, developing new approaches for non-invasive assessment of sarcopenia, is a major issue. In this project, the investigators aim to develop an automatic procedure derived from high-definition surface electromyography (HD-sEMG) technology, non-invasive and portable, for the diagnosis of sarcopenia.

03

Conditions studied

  • Sarcopenia

Browse trials for

Keywords

  • High definition surface electromyography
  • Sarcopenia
  • Muscle
04

Who can participate

Ages eligible
75 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient aged 75 years and over
  • Score ≥4 on the SARC-F screening questionnaire
  • Enrolled in a social security plan (no AME)
  • Informed and consenting patient

Exclusion criteria

Exclusion Criteria:

  • ≥30 kg/m2
  • Severe psychiatric pathology or severe cognitive disorders that do not allow the performance of examinations
  • Patients who are dependent for all acts of daily life
  • Patients with a very short \<3months
  • Pace maker
  • Recent fracture or trauma of the preventing dynamic measurement of HD-sEMG recording
  • Bilateral hip prosthesis
  • Skin problem that may interfere with the recording of surface EMG activity
  • Skin allergies to plasters
  • Allergies to electrode materials (acrylate)
  • Patient under legal protection
  • Patient on state medical aid (AME : Aide Médicale d'Etat)
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
846 participants (estimated)

Study arms

  • Experimental
    Elderly patients suspected of sarcopenia

    Device: HD-sEMG · Device: Quadriceps muscle ultrasound · Other: IPAQ Physical Activity Questionnaire

Interventions

  • DeviceHD-sEMG

    High definition surface electromyography, allowing the recording of muscle activation signals sensitive to the intensity of the contraction and indirectly to the muscle strength as well as to the muscular fatigability, but also capable of measuring the modifications of the recruitment modalities of the motor units. This recording will be made on the rectus femoris during knee extension, either in the lying position or during chair rises, depending on the patient's functional state

  • DeviceQuadriceps muscle ultrasound

    Muscle Ultrasound with Philips Lumify Wireless Handheld Ultrasound for Android - Model - L12-4 linear probe, allowing performance at the patient's bed

  • OtherIPAQ Physical Activity Questionnaire

    Physical activity assessment questionnaire/adapted version for seniors

06

What researchers measure

Primary outcomes

  1. Diagnostic score of electromyographic signals from the rectus femoris collected by the HD-sEMG technique, differentiating sarcopenic from non-sarcopenic elderly subjects

    Time frame: Day 1- Day 7

Secondary outcomes

  1. HD-sEMG signals associated with functional recovery

    Identify HD-sEMG parameters associated with good functional recovery of autonomy at D21 and M3 of hospitalization (muscle resilience)

    Time frame: Day 21 +/-3 days

  2. HD-sEMG signals associated with functional recovery

    Identify HD-sEMG parameters associated with good functional recovery of autonomy at D21 and M3 of hospitalization (muscle resilience)

    Time frame: Day 90+/-7 days

  3. HD-sEMG signals associated with Muscle Mass Index

    Correlation between electromyographic signals from the rectus femoris collected using the HD-sEMG technique and the Muscle Mass Index measured by DEXA or Bioimpedancemetry

    Time frame: Day 1

  4. HD-sEMG signals associated with Muscle Mass Index

    Correlation between electromyographic signals from the rectus femoris collected using the HD-sEMG technique and the Muscle Mass Index measured by DEXA or Bioimpedancemetry

    Time frame: Day 7

  5. HD-sEMG signals associated with grip strength

    Correlation between electromyographic signals from the rectus femoris collected using the HD-sEMG technique and grip strength measured using manual hydraulic dynamometer

    Time frame: Day 1

  6. HD-sEMG signals associated with grip strength

    Correlation between electromyographic signals from the rectus femoris collected using the HD-sEMG technique and grip strength measured using manual hydraulic dynamometer

    Time frame: Day 7

  7. HD-sEMG signals associated with physical performance

    Correlation between electromyographic signals from the rectus femoris collected using the HD-sEMG technique and the physical performance measured using Short Physical Performance Battery score (bad physical performance if score ≤ 8).

    Time frame: Day 1

  8. HD-sEMG signals associated with physical performance

    Correlation between electromyographic signals from the rectus femoris collected using the HD-sEMG technique and the physical performance measured using Short Physical Performance Battery score (bad physical performance if score ≤ 8).

    Time frame: Day 7

  9. HD-sEMG signals associated with quadriceps muscle and subcutaneous fat thickness

    Correlation between electromyographic signals from the rectus femoris collected using the HD-sEMG technique and quadriceps muscle and subcutaneous fat thickness measured using portable ultrasound).

    Time frame: Day 1

  10. HD-sEMG signals associated with quadriceps muscle and subcutaneous fat thickness

    Correlation between electromyographic signals from the rectus femoris collected using the HD-sEMG technique and quadriceps muscle and subcutaneous fat thickness measured using portable ultrasound).

    Time frame: Day 7

  11. Progress in muscle parameters

    Changes in muscle parameters mentioned above, between the D0 and D21.

    Time frame: Day 21 +/-3 days

  12. Correlation between muscle parameters and in-hospital complications

    Study the relationship between muscle parameters and in-hospital complications. (cardiovascular, pulmonary and thromboembolic diseases)

    Time frame: Day 21 +/-3 days

  13. Correlation between muscle parameters and quality of life

    Study the relationship between muscle parameters and quality of life measured using EQD5 scale (EuroQol-5D; 0-20: higher scores mean a worse outcome).

    Time frame: Day 1

  14. Correlation between muscle parameters and quality of life

    Study the relationship between muscle parameters and quality of life measured using EQD5 scale (EuroQol-5D; 0-20: higher scores mean a worse outcome).

    Time frame: Day 21 +/-3 days

  15. Correlation between muscle parameters and quality of life

    Study the relationship between muscle parameters and quality of life measured using EQD5 scale (EuroQol-5D; 0-20: higher scores mean a worse outcome).

    Time frame: Day 90+/-7 days

07

Study locations

10 of 11 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — The procedures carried out with the French data privacy authority (CNIL, Commission nationale de l'informatique et des libertés) do not provide for the transmission of the database, nor do the information and consent documents signed by the patients. Consultation by the editorial board or interested researchers of individual participant data that underlie the results reported in the article after deidentification may nevertheless be considered, subject to prior determination of the terms and conditions of such consultation and in respect for compliance with the applicable regulations.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

Time frame: Beginning 3 months and ending 3 years following article publication. Requests out of these time frame can also be submitted to the sponsor

Access criteria: Researchers who provide a methodologically sound proposal.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2025 (actual). Primary completion is estimated for Mar 2027, 20 months after the start.

Of 497 non-industry interventional studies with no phase under Sarcopenia, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 34. This study's planned 20 months is above that.

Counting every sponsor, half of 509 studies reached it within 18 months; a quarter within 8 and three quarters within 34.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 12, 2024
First posted
May 9, 2025
StartActual
Jul 9, 2025
Primary completionEst.
Mar 2027
CompletionEst.
Mar 2027
Last update
Feb 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06963359
Collaborators
Compiègne University of Technology, Centre National de la Recherche Scientifique, France
Responsible party
Sponsor
First posted
May 9, 2025
Start date
Jul 9, 2025
Primary completion
Mar 2027 (estimated)
Completion
Mar 2027 (estimated)
Last update
Feb 13, 2026

Study contacts

Kiyoka KINUGAWA, Prof. MD PhD
Contact
kiyoka.kinugawa@aphp.fr
+331 49 59 47 53
Sofiane BOUDAOUD, Prof. PhD
Contact
sofiane.boudaoud@utc.fr
+(33) 03 44 23 79 29

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion